Search 

Founded in 2007, T&W Group specializes in developing, manufacturing and supplying fine chemicals in Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals. We also have R&D center focusing on CDMO projects for our customer.

Swissaustral is a worldwide specialist in Extreme Biotechnology developing innovative solutions for non-standard technological challenges in Life Sciences and different areas of Industry. Our company exploits the potential of extremophilic microorganisms and their unexplored metabolic pathways as a unique and diverse natural source for biocompounds of various industrial applications going from pharmaceutical, chemical, food and biotechnology.

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

TheraIndx Life Sciences is a preclinical Contract Research Services Company based in Bangalore, India with Management team who have worked in Global Pharma in Drug Discovery and development progressing molecules from discovery to clinic. TheraIndx offers modular and integrated drug Discovery and development services to Pharma, Biotech and academic institutions across the globe. TheraIndx offers a wide range of animal disease models in infection, oncology, CNS and metabolic disorders along with Biomarker assays. Our Business models are Fee for services and also in partnerships till IND filing.

TissUse is a Berlin, Germany-based, vibrant growth company who has developed a unique "Multi-Organ-Chip" platform that provides unprecdented preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide a completely new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
TissUse is additionally applying its platform and know-how to develop spin-off programs in a variety of tissue and organ repair areas starting with the cosmetic market of hair transplants.

A publicly-traded bioceutical research, development and marketing firm with over 40 products backed by a combined $68 million in research and development and clinical studies. TRICCAR solutions support health challenges affecting over 6 billion people worldwide, beginning with four products to be introduced in 2021:

AVL™ - Antiviral immunity support
Global audience size: 6.2+ billion

CAL™ - Calcium deficiency
Global audience size: 6+ billion

OFF™ - Weight and obesity management
Global audience size: 1+ billion

CLM™ - Menopausal support
Global audience size: 500+ million

Having met 85%> effectiveness in placebo-based, double-blind studies, TRICCAR’s products are ready for market introduction as over-the-counter, direct-to-consumer bioceutical products. An additional 8 products will undergo Food and Drug Administration (FDA) approval. Our initial four products are targeted towards women, ages 25-65, yet appeal to all demographics and genders.

We sell via our patented and patent-pending direct-to-consumer marketing technologies that have historically generated $18 in revenue for every $1 spent compared to industry averages of $2 for every $1 spent. We add to these efforts with retail (ex. Walgreens, CVS, COSTCO, etc.) and online marketplaces (ex. Walmart.com, Amazon.com), and a 130,000 physician/chiropractor network.

Our Series B Convertible Preferred PIPE offering minimizes investor risk while providing significant potential upside. TRICCAR anticipates 3-year total revenue to exceed $163.2 million. Based on comparable price/sales valuations, this could indicate a market cap of approximately $403.5 million at time of conversion.

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders

医疗基金

A venture capital fund focused on healthcare industry.